SAFETY DATA SHEET

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Tigecycline for Injection

Product Code(s) WP00030
Synonyms Tigecycline For Injection for intravenous use
Trade Name: TYGACIL; TYZEL
Compound Number WAY-156936; GAR-936
Chemical Family: Tetracycline derivative

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification

Serious eye damage/eye irritation	Category 1 - (H318)
Skin sensitization	Category 1 - (H317)
Reproductive toxicity	Category 1A - (H360D)
Acute aquatic toxicity	Category 1 - (H400)
Chronic aquatic toxicity	Category 1 - (H410)

2.2. Label elements

Signal word Danger

Hazard statements
H317 - May cause an allergic skin reaction
H318 - Causes serious eye damage
H360D - May damage the unborn child
H410 - Very toxic to aquatic life with long lasting effects

Precautionary Statements
P202 - Do not handle until all safety precautions have been read and understood
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P280 - Wear protective gloves/protective clothing/eye protection/face protection

P363 - Wash contaminated clothing before reuse
P272 - Contaminated work clothing must not be allowed out of the workplace
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P310 - Immediately call a POISON CENTRE or doctor/physician
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P273 - Avoid release to the environment
P391 - Collect spillage
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Tigecycline (CAS #: 220620-09-7)	30 - 33		Not Listed	Repr. 1A(H360D) Skin Sens.1(H317) Eye Dam.1(H318) Aquatic Acute 1 (H400) Aquatic Chronic 1 (H410)	Not Listed	1	1
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5%	No data available	No data available

					Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%		
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Lactose NF, monohydrate (CAS #: 64044-51-5)	*	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information

+ Substance with a Union workplace exposure limit
* Proprietary
** to adjust pH
Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media	Use carbon dioxide, dry chemical, or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products	Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

5.3. Advice for firefighters

Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders	Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Avoid use of a filtered vacuum to clean spills of dry solids. Contain the source of the spill or leak. Clean spill area thoroughly. Collect spilled material by a method that controls dust generation.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections	See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling
Minimize dust generation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits
Refer to available public information for specific member state Occupational Exposure Limits.

Tigecycline
Pfizer OEL TWA-8 Hr: 100 µg/m³, Sensitizer,, Severe Eye Irritant

Sodium hydroxide

ACGIH OEL (Ceiling)	2 mg/m³
ACGIH TLV	Ceiling: 2 mg/m³
Austria	2 mg/m³
	STEL 4 mg/m³
Bulgaria	2.0 mg/m³
Czech Republic	1 mg/m³
	Ceiling: 2 mg/m³
Denmark	Ceiling: 2 mg/m³
Estonia	1 mg/m³
	STEL: 2 mg/m³
Finland	Ceiling: 2 mg/m³
France	2 mg/m³
Hungary	1 mg/m³
	STEL: 2 mg/m³
Ireland	STEL: 2 mg/m³
Ceiling Limit Value	2 mg/m³
Latvia	0.5 mg/m³
Poland	STEL: 1 mg/m³
	0.5 mg/m³
Romania	1 mg/m³
	STEL: 3 mg/m³
Slovakia	2 mg/m³
Spain	STEL: 2 mg/m³
Switzerland	2 mg/m³
	STEL: 2 mg/m³
OSHA PEL	2 mg/m³
	(vacated) Ceiling: 2 mg/m³
United Kingdom	STEL: 2 mg/m³

+ Hydrochloric Acid

ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	5 ppm

	8 mg/m³
	STEL 10 ppm
	STEL 15 mg/m³
Bulgaria	STEL: 10 ppm
	STEL: 15.0 mg/m³
	5 ppm
	8.0 mg/m³
Czech Republic	8 mg/m³
	Ceiling: 15 mg/m³
Estonia	5 ppm
	8 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
European Union	TWA: 5 ppm
	TWA: 8 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
Finland	STEL: 5 ppm
	STEL: 7.6 mg/m³
Germany	2 ppm
	3.0 mg/m³
	Ceiling / Peak: 4 ppm
	Ceiling / Peak: 6 mg/m³
Germany	2 ppm
	3 mg/m³
Hungary	8 mg/m³
	STEL: 16 mg/m³
Ireland	8 mg/m³
	5 ppm
	STEL: 10 ppm
	STEL: 15 mg/m³
Italy	5 ppm
	8 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
Ceiling Limit Value	2 ppm
	3.0 mg/m³
Latvia	5 ppm
	8 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
Netherlands	8 mg/m³
	STEL: 15 mg/m³
Poland	STEL: 10 mg/m³
	5 mg/m³
Romania	5 ppm
	8 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
Russia	MAC: 5 mg/m³
Slovakia	5 ppm
	8.0 mg/m³
Spain	5 ppm
	7.6 mg/m³
	STEL: 10 ppm
	STEL: 15 mg/m³
Switzerland	2 ppm
	3 mg/m³
	STEL: 4 ppm
	STEL: 6 mg/m³

U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m³
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m³ Ceiling: 5 ppm Ceiling: 7 mg/m³
United Kingdom	TWA: 1 ppm TWA: 2 mg/m³ STEL: 5 ppm STEL: 8 mg/m³

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

Environmental exposure controls No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection Wear safety goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Powder
Color	Orange
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

Property	**Values**
pH	No data available
Melting point / freezing point	No data available
Boiling point / boiling range	

Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

Partition Coefficient: (Method, pH, Endpoint, Value)
Tigecycline
Predicted Log P 6.7

9.2. Other information
No information available

9.2.1. Information with regard to physical hazard classes
No information available

9.2.2. Other safety characteristics
No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity
Reactivity No data available.
10.2. Chemical stability
Stability Stable under normal conditions.
Explosion data
Sensitivity to Mechanical Impact No data available.
Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions
Possibility of hazardous reactions No information available.
10.4. Conditions to avoid
Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials
Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products
Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus. High doses of tetracyclines can cause a liver condition known as fatty liver. Individuals who suffer from high cholesterol, high triglycerides, or have alcoholic liver disease may be more susceptible. May produce kidney toxicity if kidney damage already exists (based on animal data).
Known Clinical Effects:	May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Symptoms of chronic exposure to tetracyclines include redness and swelling of the skin, rash, chills, tooth discoloration, yellowing of the skin and eyes, nausea, vomiting, diarrhea, stomach pain, and chest pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Wheezing, asthma, low or high blood pressure, dizziness, lung congestion, blood changes (leukocytosis, atypical lymphocytes, toxic granulation of granulocytes and thrombocytopenia purpura), convulsion or shock may also occur. Clinical use of this drug has caused inflammation of the pancreas (pancreatitis) liver effects increased mortality Photosensitivity has been reported in some individuals taking tetracyclines.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Tigecycline

Mouse (M) IV LD50 124 mg/kg
Mouse (F) IV LD50 98 mg/kg
Rat IV LD50 106 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Irritation / Sensitization: (Study Type, Species, Severity)

Tigecycline

Antigenicity- Passive cutaneous anaphylaxis Rat Negative
Antigenicity- Passive cutaneous anaphylaxis Mouse Negative
Skin Corrosivity (*In vitro* , RHE) Not applicable Negative
Eye Irritation (*In vitro* , BCOP) Not applicable Negative
Eye Irritation Rabbit Severe
Skin Sensitization - LLNA Mouse Positive

Sodium hydroxide

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe
Eye irritation Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
Tigecycline
13 Week(s) Dog Intravenous 1.5 mg/kg/day NOAEL Lymphoid tissue
26 Week(s) Rat Intravenous 6 mg/kg/day NOAEL No effects at maximum dose
13 Week(s) Rat Intravenous 2 mg/kg/day NOAEL Lymphoid tissue

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))
Tigecycline
Embryo / Fetal Development Rabbit Intravenous 4 mg/kg/day NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Intravenous 4 mg/kg/day NOAEL Maternal Toxicity, Fetotoxicity
Embryo / Fetal Development Rabbit Intravenous 4 mg/kg/day NOAEL No effects at maximum dose
Peri-/Postnatal Development Rat Intravenous 12 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)
Tigecycline
In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative
In Vivo Micronucleus Mouse Bone Marrow Negative
In Vitro Forward Mutation Assay Mouse Lymphoma Negative
+ Hydrochloric Acid
Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

+ Hydrochloric Acid
IARC Group 3 (Not Classifiable)

11.2. Information on other hazards
11.2.1. Endocrine disrupting properties
Endocrine disrupting properties No information available.

11.2.2. Other information
Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Toxic to aquatic organisms. May cause long term adverse effects in the aquatic environment.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)
Tigecycline
Daphnia magna (Water Flea) OECD EC50 48 hours 2 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 hours 1.65 mg/L
Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.
Bacterial Inhibition: (Inoculum, Method, End Point, Result)
Tigecycline
Activated sludge OECD EC50 140 mg/L (hydrolyzed tygecycline)
Activated sludge OECD EC50 58 mg/L (unhydrolyzed tygecycline)
Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)
Tigecycline
Daphnia magna (Water Flea) OECD 21 Day(s) NOEC 2.1 mg/L Reproduction
Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 0.022 mg/L Survival

Chironomus riparius (Sediment-Dwelling Midges) OECD 28 Day(s) NOEC > 94 mg/kg

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)
Tigecycline
OECD Activated sludge Ultimate (CO2 Evolution) 36 % in 46 Day(s) Inherently biodegradable
OECD Water - Sediment (various) Total System DT50 0.9-1.1 Day(s)

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)
Tigecycline
Predicted Log P 6.7

12.4. Mobility in soil

Mobility in soil

Sorption:
Tigecycline (220620-09-7)

Method	Inoculum	End Point	Result
OECD	Activated sludge	Koc	4570

Sorption: (Method, Inoculum, Sorption Endpoint, Endpoint, Results)

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects
No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number:	UN 3077
UN proper shipping name:	Environmentally Hazardous Substance, Solid, n.o.s (Tigecycline)
Transport hazard class(es):	9
Packing group:	III
Environmental Hazard(s):	Marine Pollutant

5 kg/5L Exception:
UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not subject to the dangerous goods transportation regulations by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.
* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Lactose NF, monohydrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

Tigecycline

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

EU - Biocides

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction. Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage. Reproductive toxicity-Cat.1A; H360D - May damage the unborn child. Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life. Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date 18-Mar-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.